Announcements
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
More ▼
Key statistics
On Wednesday, Axsome Therapeutics Inc (19X:FRA) closed at 67.12, 28.04% above the 52 week low of 52.42 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 67.54 |
---|---|
High | 67.54 |
Low | 67.12 |
Bid | 66.36 |
Offer | 66.76 |
Previous close | 65.92 |
Average volume | 454.00 |
---|---|
Shares outstanding | 47.37m |
Free float | 38.22m |
P/E (TTM) | -- |
Market cap | 3.46bn USD |
EPS (TTM) | -5.20 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 14:52 BST.
More ▼